PIH8 Medication Use and Hospital Admission Rates among Preterm Born Infants Compared to Full Term Born Infants  by Houweling, L.M.A. et al.
domized clinical trials (RCTs), with follow-up times from 1 to 36months. Efficacy at
three months of follow-up (estimated as the posterior median) ranged from 87.5%
for the levonorgestrel-releasing intrauterine system (LNG-IUS) to 14.2% for proges-
togens administered for less than twoweeks out of four in themenstrual cycle. The
95% credible intervals for most estimates were quite wide, mainly because of the
limited evidence formany combinations of treatment class and follow-up time and
the uncertainty from estimating %MBL80mL from other outcome data.
CONCLUSIONS: LNG-IUS and endometrial ablation have high efficacy for HMB. The
study yielded useful insights on MTC in sparse evidence networks. Diversity of
outcome measures and follow-up times in the HMB literature presented consider-
able challenges. The Bayesian credible intervals reflected the various sources of
uncertainty.
PIH4
IS SILDENAFIL – APOMORPHINE SUBLINGUAL COMBINATION SIGNIFICANTLY
MORE EFFECTIVE THAN SUBLINGUAL SILDENAFIL IN TREATING ERECTILE
DYSFUNCTION?
Solayman MH1, Badary OA1, Salem KA2, El-Hamamsy M1
1Ain Shams University, Cairo, Egypt, 2Tanta University, Tanta, Egypt
OBJECTIVES: To test the efficacy of a sildenafil (50 mg) and apomorphine (3 mg)
sublingual combination in treatingmale Erectile Dysfunction (ED) in comparison to
sublingual sildenafil (50 mg) that shows an increasing number of non-responders.
METHODS: In all, 50 eligible ED patients were enrolled into a prospective single-
blinded crossover study with two treatment periods, each of 4 weeks, separated by
a 2-weekwashout period. A randomization list in blocks in closed packetswas used
to randomize the patients to receive sildenafil then the combination or the combi-
nation then sildenafil. The primary efficacy endpoint was the percent of attempts
resulting in erection firmenough for intercourse. Other efficacy endpoints included
the percent of attempts resulting in successful intercourse, change in the score of
the 5-item version of the International Index of Erectile Function (IIEF-5) from
baseline, response to Sexual Encounter Profile (SEP) diary questions 2 and 3, and
patient’s preference (Of the two study interventions, which one did you prefer?).
RESULTS: Only 43 patients completed the whole schedule and had results evalu-
able for efficacy. Sildenafil - apomorphine combination had a significantly higher
estimate than sildenafil in regard to the mean percent of attempts resulting in
erection firm enough for intercourse (77.6% vs. 63.1%, p 0.001) and resulting in
successful intercourse (51.1% vs. 34%, p 0.001), as well as erectile function as
evaluated by the change in the median IIEF-5 score from baseline (18 vs. 15 with
baseline of 7, P0.001). Also, the proportion of affirmative answers regarding the
SEP diary was significantly higher after the combination (question 2: 79.1% vs.
55.8% P0.01 and question 3: 65.1% vs. 44.2%, P0.05). At the end of the study,
patient preference was 88.4% for the combination and 4.6% for sildenafil.
CONCLUSIONS: Sildenafil - apomorphine sublingual combinationwas significantly
more effective than sublingual sildenafil in treating ED.
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OBJECTIVES: Benign prostatic hyperplasia (BPH) is a chronic, progressive disease
with important healthcare and economic implications. 5-alpha reductase inhibi-
tors (5-ARIs), dutasteride and finasteride are effective treatments. If untreated, BPH
may lead to complications such as acute urinary retention (AUR) and the need for
surgery (NfS). The aim of this review is to compare the efficacy of dutasteride and
finasteride in reducing episodes of AUR and the NfS related to BPH. METHODS:
MEDLINE, Lilacs and the Cochrane Central Register of Controlled Trials were
searched (from inception to September 2011) to retrieve randomized clinical trials
(RCTs) and observational studies evaluating these drugs. The search included ar-
ticles published in English, Portuguese, and Spanish. Patients with confirmed di-
agnosis of BPH were included. We analyzed data from studies that reported the
number of AUR or NfS following treatment with dutasteride or finasteride.
RESULTS:The literature search identified 24 potential full-text publications; 9 RCTs
(where 9were duplicates) and 6 observational/ retrospective studies. No RCT head-
to-head comparison was found. Indirect efficacy comparison between the two
5-ARIs, based on RCTs, was deemed inappropriate due to the heterogeneity of the
patients included in the trials, differences in outcomemeasurements, study design
and combination therapies (i.e., alpha blockers) used in the studies. Direct com-
parison of dutasteride and finasteride was available from 3 retrospective cohort
studies, indicating that dutasteridemay bemore effective in reducing the episodes
of AUR (Odds ratio0.79; 95%CI0.68-0.93; p0.0042) and the NfS (Odds ratio0.77;
95%CI0.61-0.98; p0.03) relative to finasteride. CONCLUSIONS: The current evi-
dence on the efficacy of dutasteride and finasteride makes an indirect comparison
between the two 5-ARIs difficult; however, data retrieved from observational stud-
ies indicate improved clinical performance of dutasteride compared to finasteride.
PIH6
ANTIPSYCHOTIC USE AND RISK OF NURSING HOME ADMISSION AMONG
COMMUNITY-DWELLING DUAL ELIGIBLE BENEFICIARIES
Aparasu RR, Chatterjee S
University of Houston, Houston, TX, USA
OBJECTIVES: Antipsychotic agents are often used for behavioral symptoms of de-
mentia and psychoses. This study evaluated the risk of nursing home admission
associated with use of antipsychotics among community-dwelling (Medicare and
Medicaid) dual eligible beneficiaries in the United States. METHODS: The study
involved a retrospective cohort design matched on propensity score using Medi-
care and Medicaid Analytical eXtract (MAX) data from four US states. The study
population included all elderly dual eligible community dwelling beneficiaries
(aged  65 years) who initiated antipsychotics anytime during July 1, 2001 and
December 31, 2003. Antipsychotic users were followed till the occurrence of nurs-
ing home admission or, end of the study period, whichever occurred earlier. The
risk of nursing home admission was modeled using Cox proportional model and
extended Cox hazardmodel stratified onmatched pairs based on propensity score,
using typical agents as the reference category. RESULTS: Analysis of Medicaid-
Medicare community dwelling dual eligible data revealed that there were 88,989
antipsychotic users (47,090 atypical and 41, 919 typical users) in the unmatched
cohort and 60,840 users in the matched cohort (30,420 atypical and 30, 420 typical
users). The unadjusted rate of nursing home admission was 20.58% (6, 260) in the
atypical cohort and 16.15% (4, 914) in the typical cohort. The results of Cox regres-
sion [average HR, 1.29; 95% CI, 1.23 -1.34] as well as extended regression [40days:
HR, 1.15; 1.08-1.23 and40 days: HR, 1.42; 1.33-1.51] suggest that, the risk of nursing
home admission was higher among atypical users compared to typical users.
CONCLUSIONS: The higher risk of nursing home admission among atypical users
compared to typical users may be attributable to indication bias. Since atypical
antipsychotics are often used to control behavioral symptoms of dementia, it is
possible that patients with behavioral symptoms treatedwith atypical agents were
subsequently admitted to nursing homes.
PIH7
RISK OF ALL-CAUSE HOSPITALIZATION IN DUAL ELIGIBLE BENEFICIARIES
USING ANTIPSYCHOTIC AGENTS
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OBJECTIVES: Previous studies have reported differential safety and efficacy profiles
of typical and atypical antipsychotics in the elderly. The study compared the risk of
all-cause hospitalization among elderly dual eligible beneficiaries (Medicare and
Medicaid) using typical and atypical antipsychotic agents.METHODS: A retrospec-
tive cohort study designmatched on propensity scorewas used to examine the risk
of all-cause hospitalization amongdual eligible beneficiaries 65 years or older using
antipsychotic agents. The study involved use of Medicare and Medicaid Analytical
eXtract (MAX) data from four US states. New antipsychotic users were followed for
up to six months without any censoring. The risk of hospitalization was modeled
using Cox proportional model and extended Cox hazard model stratified on
matched pairs based on propensity score. RESULTS: Analysis of Medicaid-Medi-
care dual eligible data revealed that, therewere 1, 43, 617 newantipsychotic (91, 665
atypical and 51, 952 typical) users in the unmatched cohort and 84, 162 (42,081
atypical and 42,081 typical) users in the matched cohort. The unadjusted rates of
hospitalization were 27.17% and 27.96% among atypical and typical users respec-
tively. Cox hazards regression found that, users of typical antipsychotics were
marginally at a higher average risk of hospitalization compared to atypical users
[Hazard Ratio, (HR), 1.07; 95% Confidence Interval, (CI), 1.04-1.10]. Results of ex-
tended Cox regression suggest that, typical users had a higher risk of hospitaliza-
tion than atypical users within the initial 40 days of therapy [HR, 1.26; 95% CI,
1.21-1.31]. However, the risk of hospitalization decreased with prolonged typical
use [HR, 0.90; 95% CI, 0.86-0.94]. CONCLUSIONS: Overall, typical antipsychotic us-
ers were more likely to experience all-cause hospitalization than atypical users
possibly due to differential safety profiles of antipsychotics. More research is
needed to evaluate specific reasons for the health care impact of antipsychotic use
in the elderly population.
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INFANTS COMPARED TO FULL TERM BORN INFANTS
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1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Department of
Neonatology Isala Clinics, Zwolle, The Netherlands
OBJECTIVES:About 5-12% of all pregnancies inwestern countries result in preterm
birth. Preterm born infants may be at increased risk of adverse outcomes. This
study compared hospitalization andmedication use in the first year of life between
preterm and full term born infants. METHODS: Data for this study were obtained
from linking the PHARMO database network (including detailed information on
drug dispensing and hospitalization histories) with TheNetherlands Perinatal Reg-
istry (including perinatal medical case records). From this linked cohort, all pre-
term born infants (gestational age 37 weeks) between 2004-2007 were randomly
matched to 4 full term born infants on gender, month and year of birth. All infants
were followed from birth until end of data collection in PHARMO or their first
birthday, whichever occurred first. During follow-up, hospitalization and medica-
tion use was assessed. Cox proportional hazard regression models were used to
estimate the relative risk of hospitalization/medication use among preterms com-
pared to full terms. Population attributable risk percentages (PAR%) were calcu-
lated to estimate the proportion of hospitalization/medication use attributable to
prematurity. RESULTS: Among the 71,607 singletons born between 2004-2007,
4,277 (6%) were born preterm of which 90%were hospitalized at birth, compared to
55% of the full terms. Premature infants were twice more likely to be re-hospital-
ized (RR 2.0; 95%CI 1.9-2.2), specifically for respiratory related diseases. Prematurity
accounted for 6%of respiratory re-admissions. Between the age of 6-12months, the
most frequently used outpatient drugs were antibacterials and drugs for obstruc-
tive airway diseases. Premature infants were 50%more likely to receive respiratory
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medication (RR 1.5; 95%CI 1.4-1.7). Corresponding PAR%was 3%. CONCLUSIONS: In
the first year of life, preterm born infants are up to 2.0 times more likely than full
term borns to be hospitalized or use medication, especially related to respiratory
disease.
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OBJECTIVES: A dietary supplement (DS) is defined as “any product intended for
ingestion as a supplement to the diet.” These substances include vitamins, miner-
als, herbs, amino acids, and other substances. Marketing data show a dramatic
increase in DS sales in the last decade. Themost recent published literature on the
prevalence of DS use in United States was based on data from 1999-2000. There is
a need for updated literature. The objective of this study was to measure the prev-
alence of DS use and to examine associations of its use with select demographic
characteristics in the United States. METHODS: DS data from 2007–2009 National
Health and Nutrition Examination Survey (NHANES), a nationally representative,
cross-sectional survey of UShealth andnutrition,was analyzed. The proportions of
users of any DS, multivitamins/multiminerals, vitamin-B-complex, calcium, calci-
um/antacids were calculated. Bivariate and Multivariate analyses were done to
assess the relationship of DS use and some demographic/lifestyle characteristics.
RESULTS: Approximately 43% of US population reported taking DS(s) in the past
month; DSs were consumed by females (48%) more than males (38%), youngers
(0-11 years; 33%) and elders (40 years and more; 59%) more than middle age (12-39
years; 29%), more than high school educated people (56%) than less than high
school (30%), non-Hispanic Whites (50%) more than other races (average 30%).
Multivitamins/multiminerals were the most commonly consumed DS (60%) fol-
lowed by antacid, vitamin B-complex and vitamin C. In bivariate analyses non-
HispanicWhite race, older age categories,more education, and female genderwere
significantly associated with greater use of any DS. In multivariable analysis the
latter three characteristics were still associatedwith greater use.CONCLUSIONS:A
substantial proportion of the US population takes DSmainly as vitamins,minerals,
and/or other dietary supplements. This study provides detailed information for
health care professionals and researchers regarding the DS use.
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REUPTAKE INHIBITORS FROM 2004 T0 2008 AMONG ADULT WOMEN
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OBJECTIVES: Selective serotonin reuptake inhibitors (SSRIs) have been associated
with increased risk of osteoporotic-related fractures. Bisphosphonates (BPs) are
one of the recommended medications for osteoporosis and fracture prevention.
The primary objective of this study was to examine the proportion of BP users who
are also on SSRIs and to explore the relationship between concomitant use and
patient age among women aged 45 years and older. METHODS: Data from the
2004-2008 Medical Expenditure Panel Survey (MEPS) was used to examine usage
patterns of BPs and SSRIs for women aged 45 years. Analyses were based on
yearly consolidated data and prescribed medicines files. Weighed descriptive sta-
tistics were used to evaluate patterns of medications use and proportions were
reported. Age was categorized into two groups: 45-64, and 65-85 years old.
RESULTS: In the timeframe examined, 3.5% women in 2004, 3.8% in 2005, 4.0% in
2006, 3.9% in 2007, and 4.0% in 2008 received bisphosphonates. In the same period,
8.6% women in 2004, 8.5% in 2005, 8.1% in 2006, 7.4% in 2007, and 7.9% in 2008
received SSRIs. Concomitant use (BPsSSRIs) was observed in 0.4%women in 2004,
0.5% in 2005, 0.6% in 2006, 0.6% in 2007, and 0.6% in 2008. In 2006, 2007, and 2008,
concomitant use of BPsSSRIs was higher in the 65-85 age group compared to that
of 45-64 years. This pattern may be in large part due to increasing population of
older women in the United States. CONCLUSIONS: Concomitant use of BPs and
SSRIs in adult women 45 years is not uncommon and might be higher in older
postmenopausalwomen. The observed concomitant use presents drug safety chal-
lenges surrounding the bone health of postmenopausal women. Studies are
needed to investigate the potential interactive effects of SSRIs on BP therapy.
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NAITONAL CLAIM DATABASE ANALYSIS
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OBJECTIVES: Tuberous sclerous complex (TSC) is a multi-system disorder that can
affect almost any organ system in the body. The objective of this study is to exam-
ine the prevalence and incidence rates of the common co-morbid conditions
among patients with TSC.METHODS:We used a large national health care claims
database for 39 million commercially insured US populations. Patients with a TSC
claim between 2000 and 2009, and continuous enrollment 12months before and 12
months after their first TSC diagnosis were included in this analysis (These selec-
tion criteria lead to the exclusion of those at age less than one). Approximately 40
TSC related clinical conditions were identified using ICD-9 codes or CPT codes. The
prevalence and incidence rates of these conditions are assessed and reported.
RESULTS: Patients (N1249) with TSC had mean age of 33.9 years at their 1st TSC
diagnosis, and 57.5% were females. The most prevalent comorbid conditions
within the first post TSC year were vision disorders (34.8%), benign neoplasm of
skin (28.1%), seizure (16.1%), convulsion (15.0%), dyschromia (12.2%), depression
(11.1%), cardiac dysrhythmia (9.1%), anxiety (8.6%), sleep disorder (7.8%) and he-
maturia (6.3%). The conditions with highest incidence rates (per 10,000 patient
years) in the same period were benign neoplasm of skin (1,361), vision disorders
(1,017), dyschrommia (480), seizure (464), and convulsion (456); subependymal gi-
ant cell astrocytoma (160) and Cardiac rhabdomyomas (80) were also observed.
CONCLUSIONS: TSC affects multi-systems and organs, and is associated with
many comorbid conditions. Vision disorders, benign skin cancer, seizure, convul-
sion, dyschromia, depression, cardiac dysrhythmia, anxiety, sleep disorders and
hematuria are the most prevalent ones in the real world. Managing TSC could be
challenging due to its multi-system involvement. Future effort should focus on
developing treatment that treat the underlying cause of the disease.
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OBJECTIVES: To estimate the budget impact (BI) of adding a new fixed-dose com-
bination (FDC) of 0.5mg dutasteride and 0.4mg tamsulosin daily to the Regie de
L’assuranceMaladie du Quebec (RAMQ) formulary for a three year period following
its listing for the treatment of symptomatic benign prostatic hyperplasia (BPH).
METHODS: The analysis compared RAMQdrug expenditures after the introduction
of FDC (New Drug Scenario) with an alternative scenario without FDC (Reference
Scenario). Treatments in the reference scenario include alpha blockers (tamsulo-
sin, doxazosin, terazosin, alfuzosin), 5-reductase inhibitors (finasteride, dutas-
teride) and their combinations. The treated population was assumed to be equal to
the population of men in Quebec aged 50 years with moderate to severe symp-
toms of BPH (estimated at 312,448). In the primary analysis, FDC was assumed to
gain 2.5%, 5.8% and 9.3% of BPH market share in the first 3 years after listing with
75% of share gains coming from patients switching from an alpha blocker plus
dutasteride, and 25% frompatients switching from tamsulosinmonotherapy. One-
way sensitivity analysis was performed to quantify the effect of uncertainty
around the market shares assumptions. RESULTS: In the primary analysis, adding
FDC to RAMQ is projected to result in a cost saving of $0.253M over three years.
Assuming only 60% of market share comes from patients currently taking dutas-
teride plus an alpha blocker, the total incremental BI is $5.879M over 3 years. If FDC
gains 90% of itsmarket shares from dutasteride plus an alpha blocker, the BI would
results in a cost saving of $6.386M over 3 years. CONCLUSIONS: Based on this
budget impact analysis, it may be cost-saving for the RAMQ to switch patients who
are treatedwith combination therapy of separate drugs of dutasteride and an alpha
blocker to a FDC of dutasteride and tamsulosin.
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OBJECTIVES: Epilepsy affects about 3 million people in the United States and ac-
counts for $17.6 billion/year in health care costs. Many antiepileptic drugs (AEDs)
are used to treat the disease, but some patients remain refractory. We compared
annual overall and epilepsy-relatedhealth care costs between refractory and stable
epileptic adults. METHODS: We identified adults (age18years) with epilepsy re-
quiring additional AED therapy (defined as refractory) and not requiring such ther-
apy (stable) from the MarketScan claims database in 2007-2009. An index date was
selected during calendar year 2008: the date on which an additional AED was
started for refractory patients; and convenience date for stable patientswhose AED
use was unchanged in the prior year. All pharmacy and medical claims in the
post-index year were used to estimate overall costs. Claims with epilepsy in any
diagnosis fieldwere used to estimate epilepsy-related costs. Analysis of covariance
was used to compare outcomes after adjusting for baseline differences between
groups.RESULTS:We identified 1536 refractory and 8571 stable patients (age range:
18-64years; 50.7% vs. 47.6% female; mean Charlson comorbidity index: 0.7 vs. 0.5).
Comparing refractory vs. stable patients the total health care costs were $23,238
(SD:$42,894) versus $13,839 (SD:$31,355) per patient-year (PPY) and epilepsy-related
costs were $12,399 (SD: $25,773) versus $5,511 (SD:$11,730) PPY (p0.001). Of epi-
lepsy-related costs, $7,257 (SD:$25,202) versus $2,751 (SD:$11,029) PPY were medi-
cal and $5,142 (SD:$4,110) versus $2,760 (SD:$3,361) PPY for AEDs (p0.001). After
adjusting for age, gender, region, usual care physician specialty, comorbidities and
risk factors, overall costs were significantly greater in the refractory compared to
stable patients: $7187 (p0.001). CONCLUSIONS: Although both refractory and sta-
ble epilepsy patients have a high economic burden, the costs incurred by patients
with refractory disease are significantly greater. Epilepsy-related costs comprised
under 50% of total costs, suggesting a substantial burden of comorbid conditions
and/or under-identification of epilepsy-related utilization.
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